Welcome to our dedicated page for Nuo Therapeutics SEC filings (Ticker: AURX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nuo Therapeutics, Inc. (OTCQB: AURX) SEC filings page provides direct access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a reporting company, Nuo Therapeutics submits documents such as Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and proxy statements on Schedule 14A.
For a commercial-stage medical device and biomedical company focused on chronic wound care, Annual Reports (Form 10-K) and Quarterly Reports (Form 10-Q) are central sources of information. These filings typically describe the Aurix System, summarize the company’s business and risk factors, and discuss reimbursement dynamics for autologous platelet-rich plasma (PRP) therapies used in chronic wound management. They also provide audited or reviewed financial statements and details on capital structure and liquidity.
Current Reports on Form 8-K capture significant events between periodic reports. For Nuo Therapeutics, 8-K filings have included information on recapitalization and exchange agreements that simplified the capital structure, responses to mini-tender offers, and corporate governance matters such as annual meeting results and executive compensation decisions. These filings help investors track material developments affecting the company’s operations and securities.
The company’s Definitive Proxy Statements (DEF 14A) offer insight into board composition, executive compensation programs, and matters submitted to stockholders at annual meetings, including the election of directors and ratification of the independent registered public accounting firm. They also describe how stockholders can participate in corporate governance, for example by submitting proposals or director nominations.
On this page, Stock Titan pairs real-time updates from EDGAR with AI-powered summaries that highlight the key points of lengthy documents, such as complex 10-K risk factor sections or multi-item 8-Ks. Users can quickly see what each filing covers, then review the full text when deeper analysis is needed. Filings related to insider or executive matters, such as compensation decisions disclosed in 8-Ks or proxy statements, can be examined to understand how Nuo Therapeutics aligns management incentives with its chronic wound care business.
Nuo Therapeutics, Inc. reported an insider transaction by CEO/CFO and director David Jorden. On 11/28/2025, he reported a sale of 200,000 shares of common stock at $1.50 per share, leaving him with 1,946,755 shares beneficially owned directly after the trade. The filing notes that the transaction was executed as a private transaction in connection with a personal real estate transaction and that the shares involved are characterized as “restricted” securities under the Securities Act of 1933.
Nuo Therapeutics (AURX) reported Q3 2025 results showing faster top-line growth but ongoing losses and liquidity pressure. Total revenue rose to $1,032,096 from $370,951 a year ago, driven by $957,096 in product sales and $75,000 recognized from the Smith+Nephew distribution fee. Gross profit was $625,375; gross margin was 61% versus 73% last year due to low‑margin centrifuge device sales to Smith+Nephew and tariff surcharges, partly offset by fee revenue with no cost.
Operating expenses were $1,165,517, and net loss was $537,919 (basic/diluted loss per share $0.01). For the nine months, revenue reached $2,216,679 with a net loss of $1,933,736. Cash was $514,797 as of September 30, 2025, with total deferred revenue of $1,350,000 tied to the Smith+Nephew upfront distribution fee. The company raised $791,418 in a July private placement and $113,541 from option exercises. Management states substantial doubt about the ability to continue as a going concern, citing expected cash needs beyond current resources despite the new distribution agreement.
Nuo Therapeutics, Inc. announced its Annual Meeting of Stockholders for December 16, 2025 at 9 a.m. CST at its Houston headquarters. Stockholders of record at the close of business on October 27, 2025 may vote; there were 48,077,745 shares outstanding on the record date.
Three items are up for vote: elect four directors (David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer), ratify MaloneBailey LLP as independent auditor for 2025, and an advisory “say‑on‑pay” vote on named executive officer compensation. The Board recommends voting FOR all proposals, with directors elected by plurality and Proposal 2 and 3 by majority of shares present and entitled to vote.
The proxy notes MaloneBailey has served since June 7, 2024; Marcum LLP was dismissed the same day. Marcum’s prior reports included going concern explanatory paragraphs and the company identified material weaknesses tied to limited accounting resources. Director compensation resumed in 2024–2025, and effective October 1, 2025 base salaries increased to $325,000 for the CEO/CFO and $290,000 for the CSOO. Principal holders include Charles E. Sheedy 24.1% and Scott M. Pittman 11.6%.
Nuo Therapeutics, Inc. reported two governance actions: the board approved salary increases for its top executives and set the date for the 2025 Annual Meeting of Stockholders. Effective October 1, 2025, the salary for Chief Executive and Financial Officer David E. Jorden is $325,000 and the salary for Chief Scientific and Operating Officer Peter A. Clausen is $290,000. The board said the Committee considered an improvement in the company’s business and financial condition in 2025 when approving the increases.
The board fixed the Annual Meeting to be held at the company’s principal executive office on December 16, 2025. Stockholder proposals and director nominations for inclusion in the proxy materials must be received by the company’s Secretary by the close of business on October 20, 2025 and must comply with the company’s By-Laws and SEC rules.